Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linsitinib in Active Moderate to Severe Thyroid Eye Disease
2024-514449-12-00Phase 2Completed
- Sponsor
- Sling Therapeutics, Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Graves Orbitopathy (GO) comparing Linsitinib with Placebo (2 arms). Primary endpoint: Proptosis responder rate at Week 24. Started Jul 2024; status: completed.
02
Drugs
linsitinib
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2024-514449-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514449-12-00.